Status:
TERMINATED
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
Lead Sponsor:
Pfizer
Conditions:
Dementia, Vascular
Dementia, Mixed
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. T...
Detailed Description
The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects. There were no safety or efficacy concerns regarding the study medication in the decision to terminate the t...
Eligibility Criteria
Inclusion
- Subjects must meet DSM-IV-TR criteria for the clinical diagnosis of Vascular Dementia or the clinical diagnosis of dementia due to multiple etiologies.
- Subjects must have a reliable caregiver or family member who agrees to accompany the subject to all scheduled visits, provide information about the subject as required.
Exclusion
- Subjects with any current primary psychiatric diagnosis other than dementia of the Alzheimer's type or Vascular Dementia.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00174382
Start Date
June 1 2005
End Date
April 1 2008
Last Update
March 24 2015
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Belvedere, Alberta, Canada, T5C 0A3
2
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5A 4L8
3
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6A 0A5
4
Pfizer Investigational Site
Abbotsford, British Columbia, Canada, V2S 3P8